Whats new about PSMA (Prostate-specific membrane antigen): urologist´s point of view
Authors:
MUDr. Viktor Vik 1; Mgr. Pavel Šácha 2,3; MUDr. František Koukolík; DrSc. 4; doc. RNDr. Jan Konvalinka; CSc. 2,3; prof. MUDr. Dalibor Pacík; CSc. 5; Doc. MUDr. Roman Zachoval, Ph.D. 1
Authors‘ workplace:
Urologické oddělení FTN
1; Ústav organické chemie a biochemie AV ČR, Praha
2; Katedra biochemie PF UK, Praha
3; Oddělení patologie a molekulární medicíny FTN, Praha
4; Vídeňská 800, 10 9 Praha
viktor. vik@ftn. cz
4; Urologická klinika LF MU a FN Brno
5
Published in:
Urol List 2007; 5(4): 10-13
Overview
GCPII (glutamate carboxypeptidase II), also called PSMA (prostate-specific membrane antigen), is a very interesting molecule from a medical point of view. Major progress toward understanding the function of GCPII has been made in the past 10 years. Currently, it can be stated that GCPII (PSMA) is a highly specific tumor marker for prostate cancer, which correlates with differentiation of the tumor and which has prognostic potential. Furthermore, there is evidence supporting correlations between PSMA expression and angiogenesis in most solid tumors and neurological defects after ischemic attacks in the central nervous system.
Many papers have been published about the potential use of GCPII in diagnostic or therapeutic procedures. Due to the multiple functions of GCPII and its ubiquity, publications can be found in many fields, including molecular biochemistry, pharmacology, and pathology. Despite the fact that current clinical use of GCPII-based diagnostics and therapeutics is rather sparse, this topic should be of interest to clinicians, particularly urologists.
Key words:
PSMA (prostate-specific membrane antigen), GCPII (glutamate carboxypeptidase II), prostate cancer
Sources
1. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927-936.
2. Su SL, Huang IP, Fair WR et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995; 55: 1441-1443.
3. Rovenská M, Hlouchová K, šácha P et al. Tissue expression and enzymologic characterization of human prostate-specific membrane antigen and its rat and pig orthologs. Prostate 2007; in press.
4. Birtle AJ, Freeman A, Masters JRW et al. Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels < 10ng/mL. BJU Int 2005; 96: 303-307.
5. Perner S, Hofer DM, Kim R et al. Prostate-specific membrane antigene antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38: 696-701.
6. Robinson MB, Blakely RD, Couto R, Coyle JT. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterisation of a novel N-acetylated alphalinked acidic dipeptidase activity from rat brain. J Biol Chem 1987; 262: 14498-14506.
7. Luszczki JJ, Mohamed M, Czuczwar SJ. 2-phosphonometyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. Eur J Pharmacol 2006; 531: 66-73.
8. Yao V, Bacich DJ. Prostate-specific membrane antigen (PSMA) expression gives prostate cancor cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate 2006; 66: 867-875.
9. Conway RE, Petrovic N, Li Z et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006; 26: 5310-5324.
10. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002; 94: 987-996.
11. Smith-Jones PM, Vallabhajosula S, Navarro V et al. Radiolabled monoclonal antibodies specific to the extracellular domain of the prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44: 610-617.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2007 Issue 4
Most read in this issue
- Whats new about PSMA (Prostate-specific membrane antigen): urologist´s point of view
- Transrectal ultrasonography guided prostate needle biopsy
- Current methods of nephroureteroctomy
- Role of Surgery in Treatment of Locally Advanced Prostate Cancer